从业简历

张志凌，男，医学博士，副主任医师。熟练掌握各种泌尿生殖肿瘤的诊断、手术和综合治疗，尤其擅长于肾癌、膀胱癌、前列腺癌、肾盂输尿管癌、肾上腺肿瘤的综合治疗。2014-2015到美国著名的克利夫兰医学中心（Cleveland Clinic）访问学习，师从世界著名的泌尿外科专家Steven Campbell教授，主要学习肾癌的保肾手术和微创肾肿瘤冷冻消融术。回国后成功诊治了大量疑难病例，成功切除了肿瘤，保留了肾脏，获得了良好的疗效。多次受到邀请到国内外学术会议上做学术交流和报告。首次在国际上提出:1.传统的急性肾损伤分级不适用于肾部分切除后的患者，并提出改良的分级系统；2.使用光谱评分可以客观反映手术侧肾脏在肾部分切除术中急性损伤程度。该两项成果在2016年美国泌尿外科年会上报道后引起同行的广泛关注，同年该两项研究发表于泌尿外科顶级杂志欧洲泌尿外科杂志(European Urology, 影响因子:16.3)，奠定了这两项理论在肾部分切除术后肾功能评估中的重要地位。在国内外杂志发表学术论著60余篇，其中国际主流杂志50余篇，包括国际著名杂志“European Urology” “Journal of urology”、“Urology”、 “Int J Urol”和“Cancer”，得到国内外际同行一致肯定。曾多次到美国、韩国、香港、澳门进行学术交流，并多次在国内外学术会议上向同行介绍中山大学肿瘤防治中心泌尿外科对泌尿系肿瘤的诊疗经验。学术任职：广东省泌尿生殖协会委员科学研究经验：主要研究方向为泌尿系肿瘤发病机制和病因研究。对早期肾癌保留肾脏的手术和晚期肾癌的靶向治疗和免疫治疗尤为感兴趣。负责了多项国际多中心的肾癌临床试验，在肾癌综合治疗方面有丰富的经验。主持国家自然科学基金一项，参与多项省、国家自然科学基金项目。发表论文：1.Zhang Z, Zhao J, Dong W, Aguilar Palacios, Remer EM, Li J, Demirjian S, Zabell J, Campbell SC. Acute Ipsilateral Renal Dysfunction after Partial Nephrectomy in Patients with a Contralateral Kidney: Spectrum Score to Unmask Ischemic Injury. Eur Urol, 2016 Oct;70(4):692-698.2.Zhang Z, Zhao J, Dong W, Remer EM, Li J, Demirjian S, Zabell J, Campbell SC. Acute kidney injury after partial nephrectomy: Role of parenchymal mass reduction and ischemia and impact on subsequent functional recovery. Eur Urol. 2016;69(4):745-52.3.Zhang Z, Zhao J, Zabell J, Remer EM, Li J, Campbell JA, Dong W, Aguilar Palacios D, Patel T, Demirjian S Campbell SC. Proteinuria in Patients Undergoing Renal Cancer Surgery: Impact on Overall Survival and Stability of Renal Function. European Urology Focus. In press, 2016 Jan. doi:10.1016\/j.euf.2016.01.003.4.Zhang Z, Zhao J, Velet L, Ercole CE, Remer EM, Mir CM, Li J, Takagi T, Demirjian S, Campbell SC. Functional Recovery from Extended Warm Ischemia Associated with Partial Nephrectomy. Urology. 2016;87:106-13. 5.Zhao J, Zhang Z (co-first), Dong W, Remer EM, Li J, Erickson K, Patel T, Almassi N, Hinck B, Zabell J, Tourojman M, Lane BR, Campbell SC. Preoperative prediction and postoperative surgeon assessment of volume preservation with partial nephrectomy: comparison to measured volume preservation. Urology, 2016;93:124-9.6.Zhang ZL, Yu CP, Velet L Li YH, Jiang LJ, Zhou FJ. The difference in prognosis between renal sinus fat and perinephric fat invasion for pT3a renal cell carcinoma: a meta-analysis. PLoS One. 2016 Feb 18;11(2):e0149420.7.Zhang ZL, Yu CP, Li YH, Jiang LJ, Zhou FJ. Utility of SAM68 in the progression and prognosis for bladder cancer. BMC Cancer. 2015 May 6;15:364.8.Zhang ZL, Yu CP, Liu ZW, Velet L, Li YH, Jiang LJ, Zhou FJ. The importance of extranodal extension in penile cancer: a meta-analysis. BMC Cancer. 2015 Oct 28;15:815.9.Zhang ZL, Ercole CE, Remer EM, Mir CM, Takagi T, Velet L, Li JB, Demirjian S, Campbell SC. Analysis of Atrophy after Clamped Partial Nephrectomy and Potential Impact of Ischemia. Urology, 2015 Jun;85(6):1417-23.10.Jiang L, Dong P, Zhang Z(co-first), Li C, Li Y, Liao Y, Li X, Wu Z, Guo S, Mai S, Xie D, Liu Z, Zhou F. Akt phosphorylates Prohibitin 1 to mediate its mitochondrial localization and promote proliferation of bladder cancer cells. Cell death and Disease, 2015 Feb 26;6:e1660.11.Zhang ZL, Dong P, Li YH, Liu ZW, Yao K, Han H, Qin ZK, Zhou FJ. Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients. Chin J Cancer. 2014 Mar;33(3):165-71.12.Zhang ZL, Li YH, Luo JH, Liu ZW, Yao K, Dong P, Han H, Qin ZK, Chen W, Zhou FJ. Complications of radical nephrectomy for renal cell carcinoma: a retrospective study comparing transperitoneal and retroperitoneal approaches using a standardized reporting methodology in two Chinese centers. Chin J Cancer. 2013 Aug;32(8):461-8.13.Cao Y, Zhang ZL(co-first), Zhou M, Elson P, Rini B, Aydin H, Feenstra K, Tan MH, Berghuis B, Tabbey R, Resau JH, Zhou FJ, Teh BT, Qian CN. Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer. 2013 Jan 15;119(2):313-24.14.Yu C, Zhang Z(co-first), Liao W, Zhao X, Liu L, Wu Y, Liu L, Li Y, Zhong Y, Chen K, Li J, Zhou F, Song L. The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK\/ERK signaling pathway. Carcinogenesis. 2012 Mar;33(3):678-86.15.Zhang ZL, Xiong YH, Li YH, Hou GL, Liu ZW, Han H, Qin ZK, Yun JP, Zhou FJ. Reassessment of the predictive role of perivesical fat invasion in invasive bladder cancer prognosis in 151 Chinese patients. Chin Med J (Engl). 2011 Sep;124(18):2915-9.16.Zhang ZL, Chen W, Li YH, Liu ZW, Luo JH, Lau W, Tan MH, Zhou FJ. Stage T1N0M0 renal cell carcinoma: Analysis of the prognosis in Asian patients. Chin J Cancer. 2011 Nov;30(11):772-8.17.Zhang ZL, Liu ZW, Zhou FJ, Li YH, Xiong YH, Rao K, Hou GL, Han H, Qin ZK, Yu SL, Chen XF. Modified Technique to Prevent Complications Related to Stoma and Ileoureteral Anastomosis in Patients. Undergoing Ileal Conduit Diversion. Urology. 2010 Oct; 76(4):996-1000; discussion 1001. 18.Xiong YH, Zhang ZL(co-first), Li YH, Liu ZW, Hou GL, Liu Q, Yun JP, Zhang XQ, Zhou FJ. Benign pathological findings at surgery for presumed localized renal cell carcinoma in 303 Chinese Patients. Int J Urol. 2010 Jun; 17(6):517-21.19.Zhang ZL, Li YH, Xiong YH, Hou GL, Yao K, Dong P, Liu ZW, Han H, Qin ZK, Zhou FJ. Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma. Chin J Cancer. 2010 Dec;29(12):995-9.20.Zhang Z, Li J, Zheng H, Yu C, Chen J, Liu Z, Li M, Zeng M, Zhou F, Song L. Expression and Cytoplasmic Localization of SAM68 Is a Significant and Independent Prognostic Marker for Renal Cell Carcinoma. Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2685-93.21.Chen Z, Zhang J, Zhang Z (co-first), Feng Z, Wei J, Lu J, Fang Y, Liang Y, Cen J, Pan Y, Huang Y,Zhou F, Chen W, Luo J. The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2. Cell Death Dis. 2017 Jun 1;8(6):e2859.22.Dong W, Zhang Z, Zhao J, Wu J, Suk-Ouichai C, Aguilar Palacios D, Caraballo Antonio E, Babbar S, Remer EM, Li J, Isharwal S, Zabell J, Campbell SC. Excised Parenchymal Mass During Partial Nephrectomy: Functional Implications. Urology. 2017 May;103: 129-135.23.Guo S, He X, Chen Q, Yang G, Yao K, Dong P, Ye Y, Chen D, Zhang Z, Qin Z, Liu Z, Xue Y, Zhang M, Liu R, Zhou F, Han H. The C-reactive protein\/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients. BMC Cancer. 2017 Mar 6;17(1):171.24.Zhang RL, Yang JP, Peng LX, Zheng LS, Xie P, Wang MY, Cao Y, Zhang ZL, Zhou FJ, Qian CN, Bao YX. RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA. Cell Cycle. 2016 Nov 16;15(22):3094-3104.25.Zhang XK, Zhang ZL, Lu X, Yang P, Cai MY, Hu WM, Yun JP, Zhou FJ, Qian CN, Cao Y. Prognostic Significance of Preoperative Serum Lactate Dehydrogenase in Upper Urinary Tract Urothelial Carcinoma. Clin Genitourin Cancer. 2016 Aug;14(4):341-345.e326.Jiang HM, Wei JH, Zhang ZL, Fang Y, Zhou BF, Chen ZH, Lu J, Liao B, Zhou FJ, Luo JH, Chen W. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis. Int Urol Nephrol. 2016 Feb;48(2):191-9. doi: 10.1007\/s11255-015-1161-3. Review.27.Jimenez J, Zhang Z, Zhao J, Abouassaly R, Fergany A, Gong M, Kaouk J, Krishnamurthi V, Stein R, Stephenson A, Campbell SC. Surgical salvage of thermal ablation failure for renal cell carcinoma. J Urol. 2016 Mar;195(3):594-600.28.Blackwell RH, Li B, Kozel Z, Zhang Z, Zhao J, Dong W, Capodice SE, Barton G, Shah A, Wetterlin JJ, Quek ML, Campbell SC, Gupta GN. Functional Implications of Renal Tumor Enucleation Relative to Standard Partial Nephrectomy. Urology. 2017 Jan;99:162-168. 29.Huang Z, Zhang L, Chen Y, Zhang H, Yu C, Zhou F, Zhang Z, Jiang L, Li R, Ma J, Li Z, Lai Y, Lin T, Zhao X, Zhang Q, Zhang B, Ye Z, Liu S, Wang W, Liang X, Liao R, Shi W. RhoA deficiency disrupts podocyte cytoskeleton and induces podocyte apoptosis by inhibiting YAP\/dendrin signal. BMC Nephrol. 2016 Jul 7;17(1):66.30.Chen J, Yao K, Li Z, Deng C, Wang L, Yu X, Liang P, Xie Q, Chen P, Qin Z, Ye Y, Liu Z, Zhou F, Zhang Z, Han H. Establishment and characterization of a penile cancer cell line, penl1, with a deleterious TP53 mutation as a paradigm of HPVnegative penile carcinogenesis. Oncotarget. 2016 Jun 16. doi: 10.18632\/oncotarget.10098. [Epub ahead of print]31.Guo S, He X, Chen Q, Yang G, Yao K, Dong P, Ye Y, Chen D, Zhang Z, Qin Z, Liu Z, Li Z, Xue Y, Zhang M, Liu R, Zhou F, Han H. The Effect of Preoperative Apolipoprotein A-I on the Prognosis of Surgical Renal Cell Carcinoma: A Retrospective Large Sample Study. Medicine (Baltimore). 2016 Mar;95(12):e3147. 32.Sharma N, Zhang Z, Mir MC, Takagi T, Bullen J, Campbell SC, Remer EM. Comparison of 2 CT-based methods to estimated pre-and postoperative renal parenchymal volume and correlation with functional changes after partial nephrectomy. Urology. 2015 Jul;86(1):80-6.33.Rini BI, Plimack ER, Takagi T, Elson P, Wood LS, Dreicer R, Gilligan T, Garcia J, Zhang Z, Kaouk J, Krishnamurthi V, Stephenson AJ, Fergany A, Klein EA, Uzzo RG, Chen DY, Campbell SC. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol. 2015 Aug;194(2):297-30334.Mir CM, Ercole C, Takagi T, Zhang Z, Velet L, Remer EM, Demirjian S, Campbell SC. Decline in renal function after partial nephrectomy: etiology and prevention. J Urol, 2015 Jun;193(6):1889-98.35.Lane BR, Demirjian S, Derweesh IH, Takagi T, Zhang Z, Velet L, Ercole CE, Fergany AF, Campbell SC. Survival and Functional Stability of Chronic Kidney Disease Due to Surgical Removal of Nephrons: Importance of New Baseline GFR. Euro Urol, 2015 Dec;68(6):996-1003.36.Gupta GN, Boris RS, Campbell SC, Zhang Z. Tumor Enucleation for Sporadic Localized Kidney Cancer: Pro and Con. J Urol. 2015 Sep;194(3):623-5.37.Wei JH, Haddad A, Wu KJ, Zhao HW, Kapur P, Zhang ZL, Zhao LY, Chen ZH, Zhou YY, Zhou JC, Wang B, Yu YH, Cai MY, Xie D, Liao B, Li CX, Li PX, Wang ZR, Zhou FJ, Shi L, Liu QZ, Gao ZL, He DL, Chen W, Hsieh JT, Li QZ, Margulis V, Luo JH. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. Nat Commun. 2015 Oct 30;6:8699. doi: 10.1038\/ncomms9699.38.Zhang XK, Zhang ZL, Yang P, Cai MY, Hu WM, Yun JP, Zhou FJ, Qian CN, Cao Y. Tumor necrosis predicts poor clinical outcomes in patients with node-negative upper urinary tract urothelial carcinoma. Jpn J Clin Oncol. 2015 Nov;45(11):1069-75. 39.Li X, Guo S, Wu Z, Dong P, Li Y, Zhang Z, Yao K, Han H, Qin Z, Zhou F, Liu Z. Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors. World J Urol. 2015 Sep;33(9):1351-7.40.Liu JY, Li YH, Liu ZW, Zhang ZL, Ye YL, Yao K, Jiang LJ, Han H, Qin ZK, Zhou FJ. Influence of body mass index on oncological outcomes in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Int J Urol. 2014 Feb;21(2):136-42. doi: 10.1111\/iju.12208.41.Jiang L, Zhang Z, Dong P, Li Y, Yao K, Liu Z, Han H, Qin Z, Yao M, Zhou F. Efficacy of radical cystectomy plus adjuvant intraarterial chemotherapy with gemcitabine and cisplatin on locally advanced bladder cancer. Chin Med J (Engl). 2014;127(7):1249-54.42.Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, Zeng YX, Zhou FJ, Xie D. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer. 2013 Jul 19;13:349. 43.Zhang SQ, Dong P, Zhang ZL, Wu S, Guo SJ, Yao K, Li YH, Liu ZW, Han H, Qin ZK, Cai ZM, Li XX, Zhou FJ. Renal plasmacytoma: Report of a rare case and review of the literature. Oncol Lett. 2013 Jun;5(6):1839-1843.44.Liu JY, Li YH, Zhang ZL, Ye YL, Liu ZW, Yao K, Dong P, Guo SJ, Jiang LJ, Zhong MZ, Chen W, Han H, Qin ZK, Zhou FJ. Age-specific effect of gender on upper tract urothelial carcinoma outcomes. Med Oncol. 2013;30(3):640. 45.Zhang SQ, Wu S, Yao K, Dong P, Li YH, Zhang ZL, Li XX, Zhou FJ. Retroperitoneal schwannoma mimicking metastatic seminoma: case report and literature review. Chin J Cancer. 2013 Mar;32(3):149-52.46.Liu JY, Li YH, Liu ZW, Zhang ZL, Ye YL, Yao K, Han H, Qin ZK, Zhou FJ. Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurrent penile squamous cell carcinoma. Chin J Cancer. 2013 Nov;32(11):619-23.47.Liu JY, Li YH, Zhang ZL, Yao K, Ye YL, Xie D, Han H, Liu ZW, Qin ZK, Zhou FJ. The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection. World J Urol. 2013 Dec;31(6):1519-2448.Liu JY, Zhang Q, Ye YL, Li J, Chen W, Li YH, Zhang ZL, Yao K, Jiang LJ, Han H, Liu ZW, Qin ZK, Zhou FJ. Prognostic significance of tumor location and superficial urothelial bladder carcinoma history in patients with ureteral urothelial carcinoma treated with radical nephroureterectomy. Int Urol Nephrol. 2013 Apr;45(2):395-404.49.Dong P, Jiang L, Liu J, Wu Z, Guo S, Zhang Z, Zhou F, Liu Z. Induction of paclitaxel resistance by ERα mediated prohibitin mitochondrial-nuclear shuttling. PLoS One. 2013 Dec 23;8(12):e83519. 50.Liu J, Li Y, Liao Y, Mai S, Zhang Z, Liu Z, Jiang L, Zeng Y, Zhou F, Xie D. High expression of H3K27me3 is an independent predictor of worse outcome in patients with urothelial carcinoma of bladder treated with radical cystectomy. Biomed Res Int. 2013;2013:390482. 51.Cai M, Wei J, Zhang Z, Zhao H, Qiu Y, Fang Y, Gao Z, Cao J, Chen W, Zhou F, Xie D, Luo J. Impact of age on the cancer-specific survival of patients with localized renal cell carcinoma: martingale residual and competing risks analysis. PLoS One. 2012;7(10):e48489. 52.Cai MY, Luo RZ, Li YH, Dong P, Zhang ZL, Zhou FJ, Chen JW, Yun JP, Zhang CZ, Cao Y. High-expression of ZBP-89 correlates with distal metastasis and poor prognosis of patients in clear cell renal cell carcinoma. Biochem Biophys Res Commun. 2012 Oct 5;426(4):636-42.53.Liu ZW, Zhang XQ, Hou GL, Zhang ZL, Qin ZK, Han H, Zhou FJ. Primary adult intratesticular rhabdomyosarcoma: results of the treatment of six cases. Int J Urol. 2011 Feb;18(2):171-4.54.Luo JH, Zhou FJ, Xie D, Zhang ZL, Liao B, Zhao HW, Dai YP, Chen LW, Chen W. Analysis of long-term survival in patients with localized renal cell carcinoma: laparoscopic versus open radical nephrectomy. World J Urol. 2010 Jun;28(3):289-93.55.Chen MK, Qin ZK, Zhou FJ, Han H, Liu ZW, Li YH, Yao K, Hou GL, Ye YL, Zhang ZL, Tu H, Zhang XQ, Lu KS, Yang ZW. Intra-arterial chemotherapy is reliable in preventing high-risk superficial bladder cancer from recurrence and progression. J Chemother. 2009 Dec;21(6):681-6.56.Hou GL, Li YH, Zhang ZL, Xiong YH, Chen XF, Yao K, Liu ZW, Han H, Qin ZK, Zhou FJ. A modified technique for neourethral anastomosis in orthotopic neobladder reconstruction. Urology. 2009 Nov;74(5):1145-9.57.张志凌, 李永红, 陈晓峰等.肾细胞癌现代外科治疗经验总结. 中华外科杂志, 2009，47(22):1758-1759.(缺全文)58.张志凌，刘卓炜，李永红等. 根治性肾切除术治疗肾癌是否需要常规切除同侧肾上腺. 中华泌尿外科杂志. 2010，31(1): 35-37. (缺全文)59.张志凌，周芳坚，李永红等. 肾癌术后对侧肾上腺转移的诊治(附1例报告并文献复习). 现代泌尿生殖肿瘤杂志. 2010,3(5): 237-239.60.张志凌，韩辉，刘卓炜等.膀胱肾源性腺瘤1例报道并文献复习.癌症.2009, 28(5):136-137.61.张志凌，刘卓炜，李永红等.临床诊断为局限性肾癌病例中区域淋巴结转移情况分析. 现代泌尿生殖肿瘤杂志. 2009, 1(2): 89-90.62.张志凌,叶云林,周芳坚. 泌尿生殖系肿瘤诊治中需要注意的几个问题。微创泌尿外科杂志。2014,3(4): 193-196.63.张志凌,李永红,董培,刘卓炜,周芳坚. 肾后唇或前唇切开肾部分切除术治疗靠近肾门的内生型肾癌的初步经验. 中华泌尿外科杂志. 2015, 36(3), 172-174.64.周芳坚,张志凌. 肾癌保留肾单位手术的几个问题。现代泌尿生殖肿瘤杂志。2015;7(2):65-67.65.张志凌,曹云,李再尚,蒋丽娟,李永红,周芳坚. 乳头状肾癌的临床病理特征及预后分析. 中华泌尿外科杂志. 2016, 37(5): 328-330.科研基金：1.国家自然科学青年基金项目，Sam68在舒尼替尼诱导肾癌细胞凋亡中的作用及其分子机制的研究，主持。2.中山大学肿瘤防治中心临床科学家基金，PD-1抑制剂pembrolizumab孵育自体外周血淋巴细胞联合阿昔替尼治疗晚期肾细胞癌的疗效和安全性观察(研究者发起的单臂II期临床研究)，主持。3.中山大学肿瘤防治中心留学归国人员启动基金，Sam68对在舒尼替尼诱导肾癌细胞凋亡中的作用及其机制的研究，主持。4.国家自然科学基金面上项目， 抑癌基因Nkx2.8抑制膀胱癌细胞上皮-间叶转变（EMT）的分子机制，第二参与人。5.广东省自然基金面上项目， Nkx2.8抑制膀胱癌细胞上皮间叶转变（EMT）的分子机制，第二参与人。6.国家自然科学基金面上项目，RNA甲基化转移酶NSUN2对膀胱癌发生发展的调控机制研究，第四参与人。7.国家自然科学青年基金项目，RAC1基因3’端非编码区的选择性多聚腺苷酸化在膀胱癌中的作用与临床意义，第三参与人。8.广东省省自然科学基金博士启动基金，LncRNAH19作为分子支架介导转录复合物抑制E-cadherin表达促进膀胱癌细胞上皮间质转化，第三参与人。9.广东省省自然科学基金博士启动基金，Prohibitin靶向化合物FL3抑制膀胱癌增殖的机制研究，第四参与人。10.国家自然科学基金面上项目， Zic2调控Runx2促进肾癌细胞增殖和血管生成的分子机制，第三参与人。11.广东省科技计划项目面上项目，缺血预处理保护肾脏缺血再灌注损伤中ERRγ的作用及其机制研究，第三参与人。临床试验研究：1.Sub-Investigator: 在行腹部大手术患者中比较AVE5026和依诺肝素预防静脉血栓栓塞的有效性和安全性的一项跨国、多中心、随机、双盲研究。发起者：赛诺菲-安万特。2.Sub-Investigator: 比较Pazopanib和舒尼替尼对于局部晚期和\/或转移性肾细胞癌患者的有效性和安全性（方案号：VEG108844）。发起者：葛兰素史克。3.Sub-Investigator: 阿昔替尼（AG 013736）作为二线治疗用于亚洲转移性肾细胞癌患者（方案号：A4061051）。发起者：辉瑞。4.Sub-Investigator: 一项比较苹果酸舒尼替尼和安慰剂作为辅助方案治疗高复发风险RCC患者的随机、双盲、III期临床研究——苹果酸舒尼替尼辅助治疗肾细胞癌患者的临床研究（S-TRAC）（方案号：A6181109）。发起者：辉瑞。5.Sub-Investigator: 研究Pazopanib和舒尼替尼对于局部晚期和\/或转移性肾细胞癌在亚洲受试者中的有效性和安全性（方案号：VEG113078）。发起者：葛兰素史克。6.Sub-Investigator: 一项评估依维莫司作为二线疗法治疗转移性肾细胞癌患者的有效性和安全性的II期，标签公开，多中心试验（RECORD-4）（方案号：CRAD001L2404）。发起者：诺华。7.Sub-Investigator: 评价冻干膀胱灌注用卡介苗对比注射用丝裂霉素用于预防非肌层浸润性膀胱癌术后复发的有效性和安全性的随机、开放、平行对照、多中心临床试验方案。发起者：深圳万乐。8.Sub-Investigator: 高危前列腺癌患者行根治性前列腺切除术后，立即行9个月的曲普瑞林 11.25 MG 辅助内分泌治疗对比主动监测的多国（中国和俄罗斯）多中心、随机、开放、对照研究。发起者：益普生。9.Sub-Investigator: 盐酸安罗替尼胶囊对经TKI治疗无效或不耐受的晚期肾细胞癌多中心Ⅱ期临床试验方案。发起者：正大天晴。10.Sub-Investigator: 盐酸安罗替尼胶囊治疗晚期肾细胞癌随机、阳性药物平行对照、多中心Ⅱ期临床试验方案。发起者：正大天晴。参编参译著作：Campbell-Walsh泌尿外科学(第九版).北京大学医学出版社.膀胱癌.广东科技出版社.2009.临床肿瘤学（第四版），编委.

擅长领域

肾癌保肾手术和全切手术（包括腹腔镜，开放和机器人手术）；肾盂癌、输尿管癌根治性切除手术（包括腹腔镜，开放和机器人手术），前列腺癌根治术（包括腹腔镜，开放和机器人手术），腹腔镜肾上腺肿瘤手术，膀胱全切+尿流改道手术。